The Only Implantable Sensor For Long-Term Wear

Get Started

Experience A Better Way To Manage Your Diabetes

Long-Term Convenience

One sensor continuously for up to 6 months

PLAY VIDEO

Peace of Mind Accuracy

Exceptional accuracy over 6 months, including with hypoglycemia

PLAY VIDEO

Flexibility of Wear

Easy on, easy-off transmitter to fit your lifestyle**

PLAY VIDEO

Discreet Alerts

Distinct on-body vibe alerts when high or low

PLAY VIDEO

Gentle on Skin

Silicone-based fresh daily adhesive for comfort (can help reduce skin reactions)

PLAY VIDEO

Readings You Can Count On

Consistent accuracy over 6 months

PLAY VIDEO

Eversense Has Been A Real Game Changer For Mateo

Watch how Eversense helps Mateo get all the confidence, flexibility and peace of mind he needs to provide the attention his students deserve.

Break Free From

  • The weekly or bi-weekly hassle of sensor changes and site maintenance
  • Accidental sensor dislodging
  • Wasting sensor when transmitter is removed and replaced
  • Ongoing CGM supplies to carry and order
  • Concerns about an adhesive having to last up to 14 days

Eversense And Other CGMs

Other CGMs

 

Short sensor life of 7-14 days

26-52 sensor changes per year

26-52 ‘Day 1’ warm-up periods

Need to self-insert the sensor

Transmitter must remain adhered to skin for sensor duration

Percutaneous sensor can be dislodged during everyday activities

Acrylate-based adhesives can cause skin
irritation

Eversense

 

6-month sensor life

2 sensor changes per year

Only 2 ‘Day1’ warm up periods

Sensor insertion by an Eversense Inserter

Transmitter is removable** and provides unique on-body vibe alerts

Sensor stays put no matter what

Reduced irritation with gentle, silicone-based adhesive1

Clinically Proven
Accurate Through 6 Months2

Multi-site prospective pivotal clinical trial of 180 type 1 and type 2 diabetes participants.

Accurate, Stable Performance up to 6 Months2

Percent of readings within 15 mg/dL or 15% of reference value

Eversense 6-month CGM glucose data infographic

SENSOR DAYS

Proven high users acceptability

85%

Reported improved confidence over control of their diabetes3

86%

Reported less day-to-day burden3

 

80%

were more motivated to keep up with diabetes management3

84%

of users would choose to be inserted again3

Woman sitting on the stairs while using the Eversense CGM app with her implantable CGM.

"It's Not Just The Physical Relief, But The Peace Of Mind I Have Now.***"

- Dianne, Eversense CGM User -

HEAR MORE FROM PATIENTS

FAQ

Search our most commonly asked questions for quick answers.

VIEW FAQS
Man typing on the computer for CGM device information and how does a CGM work.

Coverage

Learn more about insurance coverage and eligibility.

VIEW COVERAGE
Woman using her phone to research coverage for an implantable CGM.

*Up to 6 months
**There is no glucose data generated when the transmitter is removed
***The opinions expressed belong solely to the individual. This information provides general information only. It is not intended to be used as medical advice, diagnosis or treatment and should not replace the advice of a Health Care Provider
MARD is the mean absolute relative difference between sensor readings and matched reference values; the lower the MARD, the better the accuracy of the sensors being evaluated

1. Sanchez P, Ghosh-Dastidar S, Tweden K, Kaufman F. Real-World Data from the First US Commercial Users of an Implantable Continuous Glucose Sensor. Diabetes Technol Ther. Published online August 12, 2019, DOI:10.1089/dia.2019.0234.
2. Garg, S. K. et al. (2021). Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continous Glucose Monitoring System: The PROMISE Study. Diabetes Technology & Therapeutics, 24(2), 1–9. DOI: 10.1089/dia.2021.0182.
3. Barnard et al. Acceptability of Implantable Continuous Glucose Monitoring Sensor. Journal of Diabetes Science and Technology 2018, Vol. 12(3) 634–638.

 

Disclaimer

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For safety information click here.

Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.

Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.

Get Started